Linezolid for infective endocarditis: A structured approach based on a national database experience.

dc.contributor.authorMuñoz, P
dc.contributor.authorDe la Villa, S
dc.contributor.authorMartínez-Sellés, M
dc.contributor.authorGoenaga, M A
dc.contributor.authorReviejo-Jaka, K
dc.contributor.authorRevillas, F Arnáiz de Las
dc.contributor.authorGarcía-Cuello, L
dc.contributor.authorHidalgo-Tenorio, C
dc.contributor.authorRodríguez-Esteban, M A
dc.contributor.authorAntorrena, I
dc.contributor.authorCastelo-Corral, L
dc.contributor.authorGarcía-Vázquez, E
dc.contributor.authorDe la Torre, J
dc.contributor.authorBouza, E
dc.contributor.authorSpanish Collaboration on Endocarditis- Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES)
dc.date.accessioned2025-01-07T14:32:02Z
dc.date.available2025-01-07T14:32:02Z
dc.date.issued2021
dc.description.abstractCurrent data on the frequency and efficacy of linezolid (LNZ) in infective endocarditis (IE) are based on small retrospective series. We used a national database to evaluate the effectiveness of LNZ in IE.This is a retrospective study of IE patients in the Spanish GAMES database who received LNZ. We defined 3 levels of therapeutic impact: LNZ  50% of the total treatment, and > 50% of the LNZ doses prescribed in the first weeks of treatment), and LNZ ≥ 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses.From 3467 patients included in the GAMES database, 295 (8.5%) received LNZ. After excluding 3 patients, 292 were grouped as follows for the analyses: 99 (33.9%) patients in LNZ  50% of the LNZ doses prescribed in the first weeks of treatment), and LNZ ≥ 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses.From 3467 patients included in the GAMES database, 295 (8.5%) received LNZ. After excluding 3 patients, 292 were grouped as follows for the analyses: 99 (33.9%) patients in LNZ 
dc.identifier.doi10.1097/MD.0000000000027597
dc.identifier.essn1536-5964
dc.identifier.pmcPMC8701757
dc.identifier.pmid34941026
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8701757/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.1097/md.0000000000027597
dc.identifier.urihttps://hdl.handle.net/10668/26476
dc.issue.number51
dc.journal.titleMedicine
dc.journal.titleabbreviationMedicine (Baltimore)
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de las Nieves
dc.organizationSAS - Hospital Costa del Sol
dc.page.numbere27597
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.meshAged
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshEndocarditis
dc.subject.meshEndocarditis, Bacterial
dc.subject.meshFemale
dc.subject.meshHospital Mortality
dc.subject.meshHumans
dc.subject.meshLinezolid
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshRetrospective Studies
dc.subject.meshStaphylococcal Infections
dc.subject.meshStaphylococcus aureus
dc.subject.meshTreatment Outcome
dc.titleLinezolid for infective endocarditis: A structured approach based on a national database experience.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number100

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8701757.pdf
Size:
252.67 KB
Format:
Adobe Portable Document Format